The February 2026 recall features four previously posted episodes on multiple sclerosis. The episode begins with a conversation with Dr. Wallace J. Brownle discussing whether dissemination in time is essential to diagnois relapsing MS. The discussion continues with Dr. Daniel Ontaneda regarding the 2024 revisions of the McDonald criteria for diagnosing multiple sclerosis. The episode then transitions into a conversation with Dr. Jiwon Oh about BTK inhibitors and recent data on tolebrutinib in multiple sclerosis. The episode concludes with Dr. Sandra Vukusic addressing the differences in disease-modifying therapies for female versus male patients with multiple sclerosis. Podcast link: Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing MS 2024 McDonald Criteria BTK Inhibitors in Multiple Sclerosis Treatment Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis Podcast article: Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis Disclosures can be found at Neurology.org.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.